Alamar Biosciences, Inc. (ALMR)
Nasdaq: ALMR · Laboratory Analytical Instruments · filing with the SEC since 2026
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal quarter | Q3 FY26 | Q2 FY26 | Q1 FY26 |
|---|---|---|---|
| Period ending | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 |
| Report filed | Nov 4, 2026 | Aug 11, 2026 | May 8, 2026 |
| Revenue | 33,545 | 29,427 | 26,035 |
| For lenders | |||
| Interest and dividend income | 2,169 | 1,875 | 539 |
| Interest expense on deposits and borrowings | 153 | 224 | 223 |
| Cost of revenue | 12,901 | 11,709 | 11,578 |
| Gross profit | 20,644 | 17,718 | 14,457 |
| Research and development | 16,167 | 13,817 | 13,017 |
| Selling, general and administrative | 19,616 | 17,433 | 13,787 |
| Total operating expenses | 35,783 | 31,250 | 26,804 |
| Operating income | -15,139 | -13,532 | -12,347 |
| Income before income taxes | -13,248 | -13,292 | -20,861 |
| Income tax expense | 94 | -93 | 464 |
| Net income | -13,342 | -13,199 | -21,325 |
| Earnings per share, basic | -0.19 | -0.22 | -1.74 |
| Earnings per share, diluted | -0.19 | -0.22 | -1.74 |
| Weighted average shares, basic | 69,106,367 | 58,665,055 | 12,259,811 |
| Weighted average shares, diluted | 69,106,367 | 58,665,055 | 12,259,811 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Each quarter is three months. A fourth quarter prints only where the company tagged its three months on their own; the whole year is in the annual view.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxInterest and dividend income what its loans and securities earned
us-gaap:InterestIncomeOperatingInterest expense on deposits and borrowings what it paid for the money it lends
us-gaap:InterestExpenseOperatingCost of revenue what it cost to make or buy what it sold
us-gaap:CostOfRevenueGross profit revenue less the cost of what it sold
us-gaap:GrossProfitResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseSelling, general and administrative the cost of selling and of running the company
us-gaap:SellingGeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding